TCDD mediates inhibition of p53 and activation of ERα signaling in MCF-7 cells at moderate hypoxic conditions

International Journal of Oncology

Volumn 35, Issue 2, 2009, Pages 417-424

  Seifert, Anja ^a,c   Taubert, Helge ^a   Hombach Klonisch, Sabine ^b   Fischer, Bernd ^a   Santos, Anne Navarrete ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF MANITOBA   (Canada)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

AhR; ER ; Hdm2; HIF 1; MCF 7; p53

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 5; ESTROGEN RECEPTOR ALPHA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; DUSP5 PROTEIN, HUMAN; ESR1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CELL DEATH; CELL HYPOXIA; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROMOTER REGION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; DUAL-SPECIFICITY PHOSPHATASES; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TETRACHLORODIBENZODIOXIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 69449089766     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000354     Document Type: Article

References (43)

1. Pearce ST and Jordan VC: The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 50: 3-22, 2004.
2. Matthews J and Gustafsson JA: Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl Recept Signal 4: e016, 2006.
3. Wormke M, Stoner M, Saville B, et al: The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol Cell Biol 23: 1843-1855, 2003.
4. Denison MS and Nagy SR: Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43: 309-334, 2003.
5. IARC: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Polychlorinated Dibenzo-Para-Dioxins and Polychlorinated Dibenzofurans. Lyon, France, 4-11 February 1997. IARC Monogr Eval Carcinog Risks Hum 69: 1-631, 1997.
6. Abraham K, Knoll A, Ende M, Papke O and Helge H: Intake, fecal excretion, and body burden of polychlorinated dibenzo-pdioxins and dibenzofurans in breast-fed and formula-fed infants. Pediatr Res 40: 671-679, 1996.
7. Warner M, Eskenazi B, Mocarelli P, et al: Serum dioxin concentrations and breast cancer risk in the Seveso Women's Health Study. Environ Health Perspect 110: 625-628, 2002.
8. Kewley RJ, Whitelaw ML and Chapman-Smith A: The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. Int J Biochem Cell Biol 36: 189-204, 2004.
9. Vaupel P, Briest S and Hockel M: Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr 152: 334-342, 2002.
10. Schrenk D: Impact of dioxin-type induction of drug-metabolizing enzymes on the metabolism of endo- and xenobiotics. Biochem Pharmacol 55: 1155-1162, 1998.
11. 2-regulated gene expression. FASEB J 16: 1151-1162, 2002.
12. Fels DR and Koumenis C: HIF-1alpha and p53: the ODD couple? Trends Biochem Sci 30: 426-429, 2005.
13. Horn HF and Vousden KH: Coping with stress: multiple ways to activate p53. Oncogene 26: 1306-1316, 2007.
14. Roe JS and Youn HD: The positive regulation of p53 by the tumor suppressor VHL. Cell Cycle 5: 2054-2056, 2006.
15. Wu GS: The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 3: 156-161, 2004.
16. Seifert A, Katschinski DM, Tonack S, Fischer B and Navarrete Santos A: Significance of prolyl hydroxylase 2 in the interference of aryl hydrocarbon receptor and hypoxia-Inducible factor-1alpha signaling. Chem Res Toxicol 21: 341-348, 2008.
17. Phelps M, Phillips A, Darley M and Blaydes JP: MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J Biol Chem 280: 16651-16658, 2005.
18. Hombach-Klonisch S, Pocar P, Kauffold J and Klonisch T: Dioxin exerts anti-estrogenic actions in a novel dioxin-responsive telomerase-immortalized epithelial cell line of the oorcine oviduct (TERT-OPEC). Toxicol Sci 90: 519-528, 2006.
19. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S and Rossi JJ: Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 23: 222-226, 2005.
20. Reiners JJ Jr, Lee JY, Clift RE, Dudley DT and Myrand SP: PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol Pharmacol 53: 438-445, 1998.
21. Matthews J, Almlof T, Kietz S, Leers J and Gustafsson JA: Estrogen receptor-alpha regulates SOCS-3 expression in human breast cancer cells. Biochem Biophys Res Commun 335: 168-174, 2005.
22. Khan S, Liu S, Stoner M and Safe S: Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells. Toxicol Appl Pharmacol 223: 28-38, 2007.
23. Pollenz RS, Davarinos NA and Shearer TP: Analysis of aryl hydrocarbon receptor-mediated signaling during physiological hypoxia reveals lack of competition for the aryl hydrocarbon nuclear translocator transcription factor. Mol Pharmacol 56: 1127-1137, 1999.
24. Gradin K, McGuire J, Wenger RH, et al: Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol Cell Biol 16: 5221-5231, 1996.
25. Ryan KM, Phillips AC and Vousden KH: Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13: 332-337, 2001.
26. Sayeed A, Konduri SD, Liu W, Bansal S, Li F and Das GM: Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 67: 7746-7755, 2007.
27. Paajarvi G, Viluksela M, Pohjanvirta R, Stenius U and Hogberg J: TCDD activates Mdm2 and attenuates the p53 response to DNA damaging agents. Carcinogenesis 26: 201-208, 2005.
28. Chen D, Li M, Luo J and Gu W: Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 278: 13595-13598, 2003.
29. Bond GL, Hu W, Bond EE, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602, 2004.
30. Bond GL, Hirshfield KM, Kirchhoff T, et al: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104-5110, 2006.
31. Liu G, Schwartz JA and Brooks SC: Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res 60: 1810-1814, 2000.
32. Saji S, Okumura N, Eguchi H, et al: MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem Biophys Res Commun 281: 259-265, 2001.
33. Stoner M, Saville B, Wormke M, Dean D, Burghardt R and Safe S: Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Mol Endocrinol 16: 2231-2242, 2002.
34. Ohtake F, Takeyama K, Matsumoto T, et al: Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423: 545-550, 2003.
35. Cho J, Kim D, Lee S and Lee Y: Cobalt chloride-induced estrogen receptor alpha down-regulation involves hypoxia-inducible factor-1alpha in MCF-7 human breast cancer cells. Mol Endocrinol 19: 1191-1199, 2005.
36. Cho J, Bahn JJ, Park M, Ahn W and Lee YJ: Hypoxic activation of unoccupied estrogen-receptor-alpha is mediated by hypoxia-inducible factor-1 alpha. J Steroid Biochem Mol Biol 100: 18-23, 2006.
37. Ueda K, Arakawa H and Nakamura Y: Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53. Oncogene 22: 5586-5591, 2003.
38. Mandl M, Slack DN and Keyse SM: Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol Cell Biol 25: 1830-1845, 2005.
39. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS and Katzenellenbogen JA: Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, DNA, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 20: 3120-3132, 2006.
40. Watts SW: Serotonin activates the mitogen-activated protein kinase pathway in vascular smooth muscle: use of the mitogen-activated protein kinase kinase inhibitor PD098059. J Pharmacol Exp Ther 279: 1541-1550, 1996.
41. Sekine Y, Ikeda O, Hayakawa Y, et al: DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118. Oncogene 26: 6038-6049, 2007.
42. Croker BA, Krebs DL, Zhang JG, et al: SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4: 540-545, 2003.
43. DePasquale JA: Rearrangement of the F-actin cytoskeleton in estradiol-treated MCF-7 breast carcinoma cells. Histochem Cell Biol 112: 341-350, 1999.